| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anna-Maria Smolyakova, Ayat Zagzoog, Asher L Brandt, Tallan Black, Kawthar Mohamed, Robert B Laprairi. The Endocannabinoid System and Synthetic Cannabinoids in Preclinical Models of Seizure and Epilepsy. Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society. vol 37. issue 1. 2020-03-18. PMID:31895186. |
the major receptors of the endogenous cannabinoid system (ecs)-the type 1 and 2 cannabinoid receptors (cb1r, cb2r)-have critical roles in the modulation of neurotransmitter release and inflammation, respectively; so, it is not surprising therefore that the ecs is being considered as a target for the treatment of epilepsy. |
2020-03-18 |
2023-08-13 |
Not clear |
| Yedukondalu Nalli, Mohd Saleem Dar, Nasima Bano, Javeed Ur Rasool, Aminur R Sarkar, Junaid Banday, Aadil Qadir Bhat, Basit Rafia, Ram A Vishwakarma, Mohd Jamal Dar, Asif Al. Analyzing the role of cannabinoids as modulators of Wnt/β-catenin signaling pathway for their use in the management of neuropathic pain. Bioorganic & medicinal chemistry letters. vol 29. issue 9. 2020-02-19. PMID:30871771. |
cannabinoids have been known for suppressing neuropathic pain by modulating the endo cannabinoid system. |
2020-02-19 |
2023-08-13 |
Not clear |
| Luke J Ney, Allison Matthews, Raimondo Bruno, Kim L Felmingha. Cannabinoid interventions for PTSD: Where to next? Progress in neuro-psychopharmacology & biological psychiatry. vol 93. 2020-02-14. PMID:30946942. |
despite considerable research devoted to the effect of cannabinoid modulation on ptsd symptomology, there is not a currently agreed way by which the cannabinoid system should be targeted in humans. |
2020-02-14 |
2023-08-13 |
Not clear |
| Eva Hoch, Ulrich W Preus. [Cannabis, Cannabinoids and Cannabis Use Disorders]. Fortschritte der Neurologie-Psychiatrie. vol 87. issue 12. 2019-12-19. PMID:31847034. |
this article describes the most important cannabinoids, the endogenous cannabinoid system and possible risks of cannabis if used as drug. |
2019-12-19 |
2023-08-13 |
Not clear |
| Juan A Páez, Nuria E Campill. Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's Disease and Less Well-Known Diseases. Current medicinal chemistry. vol 26. issue 18. 2019-12-02. PMID:29484980. |
the endogenous cannabinoid system is a complex signalling system that comprises transmembrane endocannabinoid receptors, their endogenous ligands (the endocannabinoids), the specific uptake mechanisms and the enzymatic systems related to their biosynthesis and degradation. |
2019-12-02 |
2023-08-13 |
Not clear |
| José A Ramos, Rosario De Miguel, Maribel Cebeira, Mariluz Hernandez, Javier Fernández-Rui. Exposure to cannabinoids in the development of endogenous cannabinoid system. Neurotoxicity research. vol 4. issue 4. 2019-11-20. PMID:12829425. |
exposure to cannabinoids in the development of endogenous cannabinoid system. |
2019-11-20 |
2023-08-12 |
Not clear |
| D S Karhson, A Y Hardan, K J Parke. Endocannabinoid signaling in social functioning: an RDoC perspective. Translational psychiatry. vol 6. issue 9. 2019-11-20. PMID:27676446. |
this article provides a critical review of the major components of the endogenous cannabinoid system (for example, primary receptors and effectors-Δ9-tetrahydrocannabinol, cannabidiol, anandamide and 2-arachidonoylglycerol) and the contributions of cannabinoid signaling to social functioning. |
2019-11-20 |
2023-08-13 |
Not clear |
| Jeremy D Hill, Viviana Zuluaga-Ramirez, Sachin Gajghate, Malika Winfield, Yuri Persidsk. Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis. British journal of pharmacology. vol 175. issue 16. 2019-10-02. PMID:29888782. |
the cannabinoid system exerts functional regulation of neural stem cell (nsc) proliferation and adult neurogenesis, yet not all effects of cannabinoid-like compounds seen can be attributed to the cannabinoid 1 (cb |
2019-10-02 |
2023-08-13 |
Not clear |
| Maria Antonietta De Luca, Liana Fattor. Therapeutic Use of Synthetic Cannabinoids: Still an OpenIssue? Clinical therapeutics. vol 40. issue 9. 2019-09-30. PMID:30180974. |
the discovery of the endogenous cannabinoid system as a neuromodulatory system composed of receptors, endogenous ligands (endocannabinoids), and enzymes responsible for their synthesis and degradation, together with recent advancements in the elucidation of cannabinoid pharmacology, has renewed interest in medicines acting on the endocannabinoid system. |
2019-09-30 |
2023-08-13 |
human |
| Jonathan Palma, Madhusudhanan Narasimhan, Josée Guindon, Khalid Benama. Supraspinal interaction between HIV-1-gp120 and cannabinoid analgesic effectiveness. Naunyn-Schmiedeberg's archives of pharmacology. vol 391. issue 10. 2019-09-10. PMID:30008083. |
these results suggest that gp120 may interact with the cannabinoid system through the descending modulatory pain pathways centered in the pag to impair the analgesic effectiveness of cannabinoids. |
2019-09-10 |
2023-08-13 |
rat |
| Deepak Cyril D'Souza, Jose Cortes-Briones, Gina Creatura, Grai Bluez, Halle Thurnauer, Emma Deaso, Kim Bielen, Toral Surti, Rajiv Radhakrishnan, Aarti Gupta, Swapnil Gupta, John Cahill, Mohamed A Sherif, Alexandros Makriyannis, Peter T Morgan, Mohini Ranganathan, Patrick D Skosni. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. The lancet. Psychiatry. vol 6. issue 1. 2019-07-26. PMID:30528676. |
one approach is to potentiate endocannabinoid signalling by inhibiting fatty acid amide hydrolase (faah), the enzyme that degrades the endocannabinoid anandamide. |
2019-07-26 |
2023-08-13 |
Not clear |
| Qihui Luo, Shanshan Chen, Juan Deng, Liangqin Shi, Chao Huang, Anchun Cheng, Wentao Liu, Jing Fang, Li Tang, Yi Geng, Zhengli Che. Endocannabinoid hydrolase and cannabinoid receptor 1 are involved in the regulation of hypothalamus-pituitary-adrenal axis in type 2 diabetes. Metabolic brain disease. vol 33. issue 5. 2019-05-07. PMID:29948652. |
the endogenous cannabinoid system (ecbs) involves in neuronal functions, and simultaneously cannabinoid receptors are almost expressed in all regions of the hypothalamus according to a spate of reports. |
2019-05-07 |
2023-08-13 |
monkey |
| Murat Çakır, Suat Tekin, Züleyha Doğanyiğit, Yavuz Erden, Merve Soytürk, Yılmaz Çiğremiş, Süleyman Sanda. Cannabinoid type 2 receptor agonist JWH-133, attenuates Okadaic acid induced spatial memory impairment and neurodegeneration in rats. Life sciences. vol 217. 2019-01-11. PMID:30500552. |
the presence of cannabinoid type 2 receptor (cb2), a member of the cannabinoid system, was detected in different regions of the brain. |
2019-01-11 |
2023-08-13 |
rat |
| G M Mandolini, M Lazzaretti, A Pigoni, L Oldani, G Delvecchio, P Brambill. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. Epidemiology and psychiatric sciences. vol 27. issue 4. 2018-11-06. PMID:29789034. |
findings to date suggest that (a) cbd may exert antipsychotic effects in schizophrenia mainly through facilitation of endocannabinoid signalling and cannabinoid receptor type 1 antagonism; (b) cbd administration may exhibit acute anxiolytic effects in patients with generalised social anxiety disorder through modification of cerebral blood flow in specific brain sites and serotonin 1a receptor agonism; (c) cbd may reduce withdrawal symptoms and cannabis/tobacco dependence through modulation of endocannabinoid, serotoninergic and glutamatergic systems; (d) the preclinical pro-cognitive effects of cbd still lack significant results in psychiatric disorders. |
2018-11-06 |
2023-08-13 |
Not clear |
| Mar Martín-Fontecha, Alba Angelina, Beate Rückert, Ainoa Rueda-Zubiaurre, Leticia Martín-Cruz, Willem van de Veen, Mübeccel Akdis, Silvia Ortega-Gutiérrez, María Luz López-Rodríguez, Cezmi A Akdis, Oscar Palomare. A Fluorescent Probe to Unravel Functional Features of Cannabinoid Receptor CB Bioconjugate chemistry. vol 29. issue 2. 2018-09-17. PMID:29314831. |
a fluorescent probe to unravel functional features of cannabinoid receptor cb the human endogenous cannabinoid system (ecs) regulates key physiological processes and alterations in its signaling pathways, and endocannabinoid levels are associated with diseases such as neurological and neuropsychiatric conditions, cancer, pain and inflammation, obesity, and metabolic and different immune related disorders. |
2018-09-17 |
2023-08-13 |
human |
| Agnieszka Polak, Ewa Harasim-Symbor, Barbara Malinowska, Irena Kasacka, Alicja Lewandowska, Adrian Chabowsk. The Endocannabinoid System Affects Myocardial Glucose Metabolism in the DOCA-Salt Model of Hypertension. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology. vol 46. issue 2. 2018-07-05. PMID:29621749. |
recent interest in the use of cannabinoids as therapeutic agents has revealed the involvement of the endogenous cannabinoid system (ecs) in the regulation of the cardiovascular system in hypertension. |
2018-07-05 |
2023-08-13 |
rat |
| Carl R Lupica, Yuhan Hu, Orrin Devinsky, Alexander F Hoffma. Cannabinoids as hippocampal network administrators. Neuropharmacology. vol 124. 2018-05-09. PMID:28392266. |
extensive pioneering studies performed in the hippocampus have greatly contributed to our knowledge of an endogenous cannabinoid system comprised of the molecular machinery necessary to process endocannabinoid lipid messengers and their associated cannabinoid receptors. |
2018-05-09 |
2023-08-13 |
Not clear |
| Helene Francois, Lola Lecr. The Role of Cannabinoid Receptors in Renal Diseases. Current medicinal chemistry. vol 25. issue 7. 2018-04-03. PMID:28901271. |
the cannabinoid system and more specifically the cannabinoid receptors 1 (cb1) and 2 (cb2) may represent a new therapeutic target in ckd. |
2018-04-03 |
2023-08-13 |
Not clear |
| Hélène François, Antoine Durrbach, Séverine Beaudreuil, Bernard Charpentier, Lola Lecr. [Role of cannabinoid receptors in renal diseases]. Nephrologie & therapeutique. vol 12 Suppl 1. 2018-01-12. PMID:26968477. |
the cannabinoid system and more specifically the cannabinoid receptors 1 (cb1) and 2 (cb2) may represent a new therapeutic target in chronic kidney disease. |
2018-01-12 |
2023-08-13 |
human |
| Aitziber Mendiguren, Erik Aostri, Joseba Pined. Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects. Life sciences. vol 192. 2018-01-08. PMID:29169951. |
the cannabinoid system is composed of gi/o protein-coupled cannabinoid type 1 receptor (cb |
2018-01-08 |
2023-08-13 |
Not clear |